Financial Performance - The company's revenue for Q3 2022 was ¥123,632,259.92, a decrease of 57.83% compared to the same period last year[5] - The net profit attributable to shareholders for Q3 2022 was ¥23,614,385.53, down 34.91% year-on-year[5] - The basic earnings per share for Q3 2022 was ¥0.13, reflecting a decline of 34.91% compared to the previous year[5] - The company experienced a 47.08% decline in total revenue year-to-date, totaling ¥527,499,913.42, primarily due to reduced sales volume[10] - Total operating revenue for the current period is ¥527,499,913.42, a decrease of 47% compared to ¥996,873,982.72 in the previous period[18] - Net profit for the current period is ¥94,955,994.70, a decline of 25% from ¥126,464,237.72 in the previous period[19] - Basic and diluted earnings per share are both ¥0.52, compared to ¥0.69 in the previous period[20] - Total comprehensive income for the current period is ¥119,796,243.86, compared to ¥125,043,625.02 in the previous period[19] Assets and Liabilities - Total assets at the end of Q3 2022 amounted to ¥694,609,470.31, a decrease of 21.69% from the end of the previous year[5] - The company's total assets as of September 30, 2022, amount to ¥694,609,470.31, a decrease from ¥887,005,037.95 at the beginning of the year[16] - Current assets decreased to ¥476,089,675.02 from ¥671,221,578.76 at the beginning of the year, reflecting a decline of approximately 29%[15] - Cash and cash equivalents decreased to ¥160,650,861.00 from ¥320,333,416.21, a reduction of about 50%[15] - Total liabilities decreased to ¥172,581,907.38 from ¥484,773,718.88, indicating a significant reduction in liabilities[17] - The company's equity attributable to shareholders increased to ¥522,027,562.93 from ¥402,231,319.07, showing a growth of approximately 30%[17] Cash Flow - The cash flow from operating activities for the year-to-date was ¥121,463,060.34, a slight decrease of 3.21%[5] - Cash flow from operating activities is ¥121,463,060.34, slightly down from ¥125,492,914.66 in the previous period[20] - The net cash flow from financing activities was negative at -¥231,646,044.21, primarily due to loan repayments[10] - The net cash flow from investment activities was -30,354,937.83, compared to -27,206,194.62 in the previous period, indicating an increase in cash outflow by approximately 8.0%[21] - The total cash inflow from financing activities was 165,311,239.11, down from 382,852,789.87, representing a decrease of about 56.8%[21] - Cash outflow for debt repayment was 352,327,536.00, which increased from 216,000,000.00, marking a rise of approximately 63.3%[21] - The net increase in cash and cash equivalents was -127,032,851.82, compared to -60,046,266.51, indicating a worsening of approximately 111.1%[21] - The ending balance of cash and cash equivalents was 155,765,216.59, down from 237,406,293.18, representing a decrease of about 34.3%[21] Shareholder Information - Total number of common shareholders at the end of the reporting period is 5, with no preferred shareholders[11] - The largest shareholder, Qingdao Haishuo Health Industry Development Co., Ltd., holds 47.30% of shares, totaling 115,317,531 shares[11] - The company has not yet completed its initial public offering, thus there are no unrestricted shareholders[11] - The company completed its initial public offering of 60,943,979 shares on October 19, 2022[13] Other Financial Metrics - The company reported a significant increase in trading financial assets, rising by 632.58% to ¥60,134,653.94 due to the purchase of structured deposits[9] - The company received government subsidies amounting to ¥14,983,190.47 year-to-date, an increase of 366.93% compared to the previous year[10] - The company reported a net profit of ¥242,967,113.50 in retained earnings, up from ¥148,011,118.80, indicating a strong performance in profitability[17] - Total operating costs for the current period are ¥430,763,438.09, down 49% from ¥853,167,225.43 in the previous period[18] - Other income increased to ¥14,983,190.47 from ¥3,208,869.00 in the previous period, showing a significant growth[18] - Investment loss for the current period is ¥6,361,368.24, compared to a gain of ¥3,263,311.43 in the previous period[18] - Sales expenses decreased to ¥21,937,904.67 from ¥32,191,950.78, reflecting a cost-cutting strategy[18] - Research and development expenses are ¥17,813,563.71, slightly down from ¥18,843,020.64 in the previous period, indicating stable investment in innovation[18] Audit Information - The company did not undergo an audit for the third quarter report[22]
三柏硕(001300) - 2022 Q3 - 季度财报